ArticleInvestigational new drugs2015

A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin.

Jhanelle E Gray et al.PubMed ↗Publisher ↗

No numbers read from the abstract.